

For the Management of Hyperlipidemia and Hypertriglyceridemia

IMPUROSE-5/10/20/40

Rosuvastatin 5 / 10 / 20 / 40 mg Tablets

IMPUROSE-F 10/20

Rosuvastatin 10 / 20 mg and Fenofibrate 160 mg Tablets



IMPUROSE-5/10/20/40

Rosuvastatin 5 | 10 | 20 | 40 mg Tablets

IMPUROSE-F 10/20

Rosuvastatin 10 / 20 mg and Fenofibrate 160 mg Tablets

Background:

Despite achieving optimal LDL-C levels with statin therapy, the risk of cardiovascular events persists in the majority of dyslipidemic patients. In particular, patients with mixed dyslipidemia, who have continued elevation of triglycerides and decreased HDL-C, have substantial residual cardiovascular risk. Thus, patients with multiple abnormal lipid parameters may require combination lipid drug therapy. Current guidelines recommend more intensive goals for LDL-C in high-risk patients, as well as combination treatment with agents that target triglycerides and HDL-C in these patients with mixed dyslipidemia. Clinical trials of Rosuvastatin plus fenofibric acid suggest that this is an efficacious and safe strategy for the treatment of mixed dyslipidemia.

Indication:

IMPUROSE / IMPUROSE-F is Indicated for diet to reduce elevated LDL-C, TC and Triglycerides and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia.

Description:

IMPUROSE-5/10/20/40 (Rosuvastatin) is an antilipidemic agent that competitively inhibits hydroxymethylglutaryl – coenzyme A (HMG-CoA) reductase to reduce cholesterol synthesis in liver.

IMPUROSE-F 10/20 contains Rosuvastatin and Fenofibrate. Both are antilipidemic agent which reduce both cholesterol and triglycerides in the blood.

Mechanism of Action:

- Rosuvastatin is a competitive inhibitor of HMG-CoA reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol biosynthesis.
- Fenofibrate exerts its therapeutic effects through activation of peroxisome proliferator activated receptor alpha (PPARα). This increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of Apoprotein C-III.
- The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles, to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly.

Dosage:

- The dose range for IMPUROSE in adults is 5 to 40 mg orally once daily or as prescribed by the Doctor.
- > The recommended daily dose of IMPUROSE-F is one tablet a day or as prescribed by the Doctor.

References:

1. Ann Pharmacother. 2002 Nov;36(11):1749-58.

2. Clin. Lipidol. (2010) 5®, 627-649

La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads, S.G. Highway, Ahmedabad-380015, Gujarat, India. Phone: + 91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998 E-mail: info@larenon.com | Web: www.larenon.com

4	l am:
0	Call me on:
	Mail me at:
©2	2023 All rights reserved. La Renon Healthcare Private Limited